Pfenex (PFNX) Tops Q4 EPS by 13c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
March 11, 2019 4:05 PM EDTWe believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors
Several significant milestones across the Companys pipeline are expected in 2019
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfnex Expression Technology platform, the Company has created an advanced pipeline... More
